Van Eck Associates Corp Bluebird Bio, Inc. Transaction History

Van Eck Associates Corp

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$34.44 - $43.75 $1.48 Million - $1.88 Million	-43,018 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$27.12 - $45.97 $490,655 - $831,689	18,092 Added 72.58%	43,018 $2.63 Million
Q1 2020 May 12, 2020	BUY	$26.16 - $63.5 $32,726 - $79,438	1,251 Added 5.28%	24,926 $1.15 Million
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $115,052 - $151,091	2,450 Added 11.54%	23,675 $2.08 Million
Q3 2019 Nov 08, 2019	SELL	$59.47 - $93.1 $49,538 - $77,552	-833 Reduced 3.78%	21,225 $1.95 Million
Q2 2019 Aug 07, 2019	SELL	$75.84 - $105.21 $1.09 Million - $1.51 Million	-14,383 Reduced 39.47%	22,058 $2.81 Million
Q1 2019 May 13, 2019	SELL	$64.44 - $104.11 $871,937 - $1.41 Million	-13,531 Reduced 27.08%	36,441 $5.73 Million
Q4 2018 Feb 12, 2019	SELL	$59.1 - $93.26 $167,666 - $264,578	-2,837 Reduced 5.37%	49,972 $4.96 Million
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $1.57 Million - $2.08 Million	17,722 Added 50.51%	52,809 $7.71 Million
Q2 2018 Aug 13, 2018	BUY	$99.64 - $127.59 $362,988 - $464,810	3,643 Added 11.59%	35,087 $5.51 Million
Q1 2018 May 11, 2018	SELL	$105.8 - $150.94 $649,929 - $927,224	-6,143 Reduced 16.34%	31,444 $5.37 Million
Q4 2017 Feb 12, 2018	SELL	$81.25 - $130.7 $1.49 Million - $2.4 Million	-18,327 Reduced 32.78%	37,587 $6.69 Million
Q3 2017 Nov 09, 2017	BUY	$57.74 - $91.42 $634,620 - $1 Million	10,991 Added 24.47%	55,914 $7.68 Million
Q2 2017 Aug 11, 2017	BUY	N/A	44,923	44,923 $4.72 Million

144

63.2M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $644M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.